^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Farydak (panobinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Based on the encouraging ORR and PFS in iMID–refractory patients, the NCCN Multiple Myeloma Panel has included panobinostat with lenalidomide and dexamethasone for patients...
